Leukemia Trial Results
Dasatinib Effective in Blast-Crisis Chronic Myeloid Leukemia
(Posted: 05/08/2007) - Dasatinib can induce lasting hematologic and cytogenetic responses in patients with the blast-crisis phase of chronic myeloid leukemia, according to the April 15, 2007, issue of Blood.
Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.
Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia
(Posted: 01/24/2007) - Positive results of a phase III cancer clinical trial in an uncommon form of leukemia were released today. The results showed that adult patients with previously untreated acute promyelocytic leukemia who had standard chemotherapy to induce remission of their disease, and then received the chemotherapy drug arsenic trioxide to maintain remission, had a significantly better event-free survival (more patients free of leukemia) and better overall survival than those who received only standard chemotherapy. The trial was sponsored by the NCI, and was led by one of its Cooperative Clinical Trials Groups -- the Cancer and Leukemia Group B.
(Posted: 05/08/2007) - Dasatinib can induce lasting hematologic and cytogenetic responses in patients with the blast-crisis phase of chronic myeloid leukemia, according to the April 15, 2007, issue of Blood.
Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.
Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia
(Posted: 01/24/2007) - Positive results of a phase III cancer clinical trial in an uncommon form of leukemia were released today. The results showed that adult patients with previously untreated acute promyelocytic leukemia who had standard chemotherapy to induce remission of their disease, and then received the chemotherapy drug arsenic trioxide to maintain remission, had a significantly better event-free survival (more patients free of leukemia) and better overall survival than those who received only standard chemotherapy. The trial was sponsored by the NCI, and was led by one of its Cooperative Clinical Trials Groups -- the Cancer and Leukemia Group B.
